Equities

Arctic Bioscience AS

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Arctic Bioscience AS

Actions
Consumer Staples Food Producers
  • Price (NOK)3.75
  • Today's Change-0.10 / -2.60%
  • Shares traded33.50k
  • 1 Year change-64.95%
  • Beta1.8128
Data delayed at least 15 minutes, as of Jul 04 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.

  • Revenue in NOK (TTM)43.48m
  • Net income in NOK-47.93m
  • Incorporated2011
  • Employees22.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Odi Pharma AB (publ)11.17m-6.12m28.71m1.00--32.25--2.57-0.3762-0.37620.68320.0530.927271.341.9810,586,660.00-50.83-36.52-267.85-46.17-17.48---54.82-104.021.13-6.270.00--15,880.00--91.77------
StenoCare A/S2.96m-52.20m34.12m8.00--8.76--11.52-1.06-1.060.05430.06370.0928--1.23232,427.50-163.58-45.69-243.50-59.64-----1,762.94-739.041.60-12.770.5391---40.60-14.70-96.30---64.95--
Double Bond Phrmcutcl Intrntnl AB (publ)687.13k-6.04m42.01m9.00--5.94--61.14-0.0597-0.05970.00620.02690.0628--11.5472,382.22-55.26-75.46-121.77-104.36776.97-717.21-879.34-1,144.39--0.00730.00---20.5235.1858.98--114.06--
ExpreS2ion Biotech Holding AB9.73m-36.52m73.46m18.00--1.36--7.55-40.28-40.285.6719.250.1106--6.69485,473.70-41.53-58.63-64.64-70.70-124.60-46.22-375.38-621.40----0.0066---11.07-10.7660.57--5.08--
Lipigon Pharmaceuticals AB10.85m-28.48m76.10m7.00--0.846--7.01-0.14-0.140.0550.15130.3309--9.161,469,571.00-86.85-860.41-106.61-1,152.75-----262.50-1,282.24----0.00---37.3042.6474.22------
Oncozenge AB2.86m-6.62m81.30m1.00--7.71--28.41-0.5355-0.53550.23160.85320.1873--1.562,713,000.00-43.29---47.77---141.25---231.18------0.00------45.37------
XP Chemistries AB354.44k-7.40m98.81m2.00--2.80--278.78-0.0585-0.05850.00260.1120.01362.886.41168,015.00-28.40---30.02---1,398.14---2,087.66--2.94--0.00---57.22--11.26------
Arctic Bioscience AS43.48m-47.93m100.72m22.00--0.4515--2.32-1.89-1.891.718.310.1501.023.601,976,528.00-16.53-15.49-20.28-17.8327.3428.52-110.23-125.490.4279-333.660.0934--28.847.68-5.31------
Pila Pharma AB817.35k-11.86m107.09m0.00--15.81--131.02-0.3885-0.38850.02720.1730.1056--4.43---153.16-113.42-188.57-128.21-763.20-118.10-1,450.69-1,491.09---154.020.00---47.0317.47-13.21------
Vivesto AB0.00-41.79m131.67m4.00--0.8315-----0.0736-0.07360.000.2790.00----0.00-21.00---23.34--------------0.00------69.12------
Oncoinvent ASA-100.00bn-100.00bn166.16m34.00--1.45----------1.17-----------55.04---64.24-------1,272.00----0.0644--39.95-6.622.38------
Enorama Pharma AB17.12m-61.61m177.04m5.00--16.28--10.34-1.05-1.050.29980.15360.44822.4430.533,245,400.00-161.35-88.96-402.83-127.92-15.5015.72-359.96-488.890.8133-12.760.00--1,061.1215.681.81------
Data as of Jul 04 2025. Currency figures normalised to Arctic Bioscience AS's reporting currency: Norwegian Krone NOK

Institutional shareholders

4.67%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Jun 20241.20m4.50%
Cicero Fonder ABas of 31 Mar 202346.52k0.17%
Data from 31 Mar 2025 - 30 May 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.